<DOC>
	<DOCNO>NCT00911287</DOCNO>
	<brief_summary>The purpose study determine oxymorphone ER effective safe treat chronic pain opioid-naive patient .</brief_summary>
	<brief_title>Oxymorphone Extended Release ( ER ) Opioid-Naive Patients With Chronic Pain</brief_title>
	<detailed_description>The purpose study assess effectiveness tolerability oxymorphone ER treatment moderate severe chronic pain opioid-naive patient . Patients gradually titrate 5mg dose oxymorphone ER ( take every 12 hour ) stabilize dose achieve . The study design open-label , nonrandomized 6-month study titration/stabilization period â‰¤ 1 month follow 5-month maintenance period .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Oxymorphone</mesh_term>
	<criteria>Currently receive stable nonopioid analgesic regimen Have initial pain intensity score great equal 40 mm 100mm Visual Analogue Scale ( VAS ) categorical pain rating moderate severe categorical scale none , mild , moderate , severe If female , must practice abstinence use medically acceptable form contraception Understand write speak English Have inform nature study provide write informed consent . Positive pregnancy test ( female ) History active asthma emphysema Clinically significant hepatic impairment Received following medication within 48 hour prior dosing : Dextromethorphancontaining medication ( overthecounter [ OTC ] cough cold preparation , Vicks Formula 44 ) St. John 's Wort &gt; 1000 mg/day Received monoamine oxidase inhibitor ( MAOI ) drug within 2 week prior dose Are stabilize follow medication least 4 week prior dose : Tricyclic antidepressant drug Serotonin reuptake inhibitor Amphetamines use attentiondeficit/hyperactivity disorder ( ADHD ) History alcohol substance abuse within last 3 year History opioid abuse within 6 month prior study entry Have know oxymorphone sensitivity allergy Have schedule elective surgery procedure study would permit continuation study medication , and/ require another analgesic currently take patient Have receive investigational drug product participate investigational drug study within period 30 day prior receive study medication Have know allergy significant reaction opioids Have participant previous oxymorphone clinical trial Have history seizure ( Patients history juvenile febrile seizure may include seizure history within past 10 year ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Chronic pain</keyword>
	<keyword>Extended Release</keyword>
	<keyword>Long-Acting Opioid</keyword>
	<keyword>Opioid</keyword>
	<keyword>Opioid-Naive</keyword>
	<keyword>Oxymorphone</keyword>
</DOC>